Gender Differences in Physical Morbidity in Opioid Agonist Treatment Patients: Population-based Cohort Studies from the Czech Republic and Norway

Overview

Journal Subst Abuse Treat Prev Policy

Publisher Biomed Central

Specialty Psychiatry

Date 2023 Jul 28

PMID 37507709

Authors

Gabriela Rolova

Desiree Eide

Roman Gabrhelik

Ingvild Odsbu

Thomas Clausen

Svetlana Skurtveit

Affiliations

Soon will be listed here.

Abstract

Background: Physical diseases represent a significant burden for opioid agonist treatment (OAT) patients. This study described physical morbidity in two national cohorts of OAT patients focusing on gender differences.

Methods: This population-based cohort study linking multiple health registers investigated physical diseases (ICD-10) in patients receiving OAT in the Czech Republic (N = 4,280) and Norway (N = 11,389) during 2010-2019. Gender-stratified analysis was performed.

Results: Overall, we found a large burden of physical morbidity across gender groups in OAT patients. In the Czech Republic and Norway, women in OAT had a significantly higher prevalence of physical diseases across most diagnostic chapters, notably genitourinary diseases and neoplasms. Injuries/external causes and infectious/parasitic diseases were among the most common diseases in both women and men. Viral hepatitis accounted for over half of infectious morbidity in women and men in both cohorts.

Conclusions: Our findings support the need for early screening, detection, and treatment of diseases and conditions across organ systems and the integration of health promotion activities to reduce physical morbidity in OAT patients. The gender differences underline the need for a tailored approach to address specific medical conditions.

Citing Articles

Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway.

Rolova G, Skurtveit S, Gabrhelik R, Mravcik V, Odsbu I Addict Sci Clin Pract. 2024; 19(1):37.

PMID: 38741162 PMC: 11092244. DOI: 10.1186/s13722-024-00467-5.

Pediatric Acute Mastoiditis in Saudi Arabia: Demographic Insights, Clinical Profiles, and Prognostic Factors.

Alshehri S, Alahmari K Children (Basel). 2024; 11(4).

PMID: 38671619 PMC: 11048861. DOI: 10.3390/children11040402.

References

Skeie I, Brekke M, Lindbaek M, Waal H . Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study. BMC Public Health. 2008; 8:43. PMC: 2253538. DOI: 10.1186/1471-2458-8-43. View

Medved D, Clausen T, Bukten A, Bjornestad R, Muller A . Large and non-specific somatic disease burdens among ageing, long-term opioid maintenance treatment patients. Subst Abuse Treat Prev Policy. 2020; 15(1):87. PMC: 7667746. DOI: 10.1186/s13011-020-00311-4. View

Compton W, Thomas Y, Stinson F, Grant B . Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007; 64(5):566-76. DOI: 10.1001/archpsyc.64.5.566. View

McHugh R, Votaw V, Sugarman D, Greenfield S . Sex and gender differences in substance use disorders. Clin Psychol Rev. 2017; 66:12-23. PMC: 5945349. DOI: 10.1016/j.cpr.2017.10.012. View

Amato L, Davoli M, Perucci C, Ferri M, Faggiano F, Mattick R . An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005; 28(4):321-9. DOI: 10.1016/j.jsat.2005.02.007. View

Guydish J, Passalacqua E, Pagano A, Martinez C, Le T, Chun J . An international systematic review of smoking prevalence in addiction treatment. Addiction. 2015; 111(2):220-30. PMC: 4990064. DOI: 10.1111/add.13099. View

Roth G, Mensah G, Johnson C, Addolorato G, Ammirati E, Baddour L . Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25):2982-3021. PMC: 7755038. DOI: 10.1016/j.jacc.2020.11.010. View

Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall B . Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019; 394(10208):1560-1579. PMC: 7068135. DOI: 10.1016/S0140-6736(19)32229-9. View

Lewer D, Harris M, Hope V . Opiate Injection-Associated Skin, Soft Tissue, and Vascular Infections, England, UK, 1997-2016. Emerg Infect Dis. 2017; 23(8):1400-1403. PMC: 5547794. DOI: 10.3201/eid2308.170439. View

10.

Vigna-Taglianti F, Burroni P, Mathis F, Versino E, Beccaria F, Rotelli M . Gender Differences in Heroin Addiction and Treatment: Results from the VEdeTTE Cohort. Subst Use Misuse. 2016; 51(3):295-309. DOI: 10.3109/10826084.2015.1108339. View

11.

Bakken I, Ariansen A, Knudsen G, Johansen K, Vollset S . The Norwegian Patient Registry and the Norwegian Registry for Primary Health Care: Research potential of two nationwide health-care registries. Scand J Public Health. 2019; 48(1):49-55. DOI: 10.1177/1403494819859737. View

12.

Bjornestad E, Vederhus J, Clausen T . High smoking and low cessation rates among patients in treatment for opioid and other substance use disorders. BMC Psychiatry. 2022; 22(1):649. PMC: 9583489. DOI: 10.1186/s12888-022-04283-6. View

13.

Grella C, Lovinger K . Gender differences in physical and mental health outcomes among an aging cohort of individuals with a history of heroin dependence. Addict Behav. 2011; 37(3):306-12. PMC: 3258372. DOI: 10.1016/j.addbeh.2011.11.028. View

14.

Puigdollers E, Domingo-Salvany A, Brugal M, Torrens M, Alvaros J, Castillo C . Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse. 2004; 39(9):1353-68. DOI: 10.1081/ja-120039392. View

15.

Pathan H, Williams J . Basic opioid pharmacology: an update. Br J Pain. 2015; 6(1):11-6. PMC: 4590096. DOI: 10.1177/2049463712438493. View

16.

Darnall B, Stacey B, Chou R . Medical and psychological risks and consequences of long-term opioid therapy in women. Pain Med. 2012; 13(9):1181-211. PMC: 4801003. DOI: 10.1111/j.1526-4637.2012.01467.x. View

17.

Stringer J, Welsh C, Tommasello A . Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm. 2009; 66(9):825-33. DOI: 10.2146/ajhp070392. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Gabrhelik R, Handal M, Mravcik V, Nechanska B, Tjagvad C, Thylstrup B . Opioid maintenance treatment in the Czech Republic, Norway and Denmark: a study protocol of a comparative registry linkage study. BMJ Open. 2021; 11(5):e047028. PMC: 8112418. DOI: 10.1136/bmjopen-2020-047028. View

20.

Soyka M . Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment. Eur Addict Res. 2014; 21(2):78-87. DOI: 10.1159/000363232. View